Cryptococcal Antigen Screening Among Antiretroviral Therapy–Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda

Simple item page
dc.contributor.authorBaruch Baluku, Joseph
dc.contributor.authorMugabe, Pallen
dc.contributor.authorMwebaza, Shem
dc.contributor.authorNakaweesi, Jane
dc.contributor.authorSenyimba, Catherine
dc.contributor.authorOpio, Joel Peter
dc.contributor.authorMukasa, Barbara
dc.date.accessioned2022-05-03T00:27:15Z
dc.date.available2022-05-03T00:27:15Z
dc.date.issued2021
dc.description.abstractThe World Health Organization recommends screening for the cryptococcal antigen (CrAg), a predictor of cryptococcal meningitis, among antiretroviral therapy (ART)–naïve people with HIV (PWH) with CD4 <100 cells/mm3. CrAg positivity among ART-experienced PWH with viral load (VL) nonsuppression is not well established, yet high VLs are associated with cryptococcal meningitis independent of CD4 count. We compared the frequency and positivity yield of CrAg screening among ART-experienced PWH with VL nonsuppression and ART-naïve PWH with CD4 <100 cells/mm3 attending rural public health facilities in Uganda. Methods. We reviewed routinely generated programmatic reports on cryptococcal disease screening from 104 health facilities in 8 rural districts of Uganda from January 2018 to July 2019. A lateral flow assay (IMMY CrAg) was used to screen for cryptococcal disease. PWH were eligible for CrAg screening if they were ART-naïve with CD4 <100 cell/mm3 or ART-experienced with an HIV VL >1000 copies/mL after at least 6 months of ART. We used Pearson’s chi-square test to compare the frequency and yield of CrAg screening. Results. Of 71 860 ART-experienced PWH, 7210 (10.0%) were eligible for CrAg screening. Among 15 417 ART-naïve PWH, 5719 (37.1%) had a CD4 count measurement, of whom 937 (16.4%) were eligible for CrAg screening. The frequency of CrAg screening was 11.5% (830/7210) among eligible ART-experienced PWH compared with 95.1% (891/937) of eligible ART- naïve PWH (P < .001). The CrAg positivity yield was 10.5% among eligible ART-experienced PWH compared with 13.8% among eligible ART-naïve PWH (P = .035). Conclusions. The low frequency and high positivity yield of CrAg screening among ART-experienced PWH with VL nonsuppression suggest a need for VL- directed CrAg screening in this population. Studies are needed to evaluate the cost-effectiveness and impact of CrAg screening and fluconazole prophylaxis on the outcomes of ART-experienced PWH with VL nonsuppression.en_US
dc.identifier.citationBaluku, J. B., Mugabe, P., Mwebaza, S., Nakaweesi, J., Senyimba, C., Opio, J. P., & Mukasa, B. (2021, February). Cryptococcal Antigen Screening Among Antiretroviral Therapy–Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda. In Open Forum Infectious Diseases (Vol. 8, No. 2, p. ofab010). US: Oxford University Press. DOI: 10.1093/ofid/ofab010en_US
dc.identifier.other10.1093/ofid/ofab010
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3194
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.subjectART-experienceden_US
dc.subjectViral loaden_US
dc.subjectNonsuppressionen_US
dc.subjectHIVen_US
dc.subjectCrAgen_US
dc.subjectCryptococcal meningitisen_US
dc.titleCryptococcal Antigen Screening Among Antiretroviral Therapy–Experienced People With HIV With Viral Load Nonsuppression in Rural Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cryptococcal Antigen Screening Among Antiretroviral.pdf
Size:
217.1 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences